AstraZeneca and MSD’s Lynparza (olaparib) has shown efficacy in preventing cancer recurrence in patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.
According to results from the OlympiA Phase III trial, published in The New England Journal of Medicine and in line for presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on June 6, the drug demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival (iDFS) versus placebo in the adjuvant treatment setting.
In the overall trial population of patients who had completed local treatment and standard neoadjuvant or adjuvant chemotherapy, data showed Lynparza cut the risk of invasive breast cancer recurrences, second cancers or death by 42%.
At three years, 85.9% of patients treated with Lynparza remained alive and free of invasive breast cancer and second cancers versus 77.1% on placebo.
“While there have been great strides in the early treatment of breast cancer, the fear of cancer returning is still at the forefront of patients’ minds,” commented Sue Friedman, executive director, Facing Our Risk of Cancer Empowered (FORCE) and member of the OlympiA trial steering committee. “New targeted treatment approaches are needed in the adjuvant setting that can help keep cancer and that fear at bay.”
Dave Fredrickson, executive vice president, Oncology Business Unit, at AZ, said: “This is the first time that any medicine targeting a BRCA mutation has demonstrated the potential to change the course of early-stage breast cancer and offer hope for a cure. By providing a treatment which significantly reduces the risk of breast cancer returning in these high-risk patients, we hope Lynparza will set a new benchmark demonstrating sustained clinical benefit. “We are working with regulatory authorities to bring Lynparza to these patients as quickly as possible.”
Roy Baynes, senior vice president and head of Global Clinical Development, chief medical officer, MSD Research Laboratories, also noted that the data “support the importance of testing at diagnosis for BRCA1/2 mutations, which are actionable biomarkers that can help identify patients with early breast cancer who may be eligible for adjuvant treatment with Lynparza.”
An estimated 2.3 million people were diagnosed with breast cancer worldwide in 2020 and BRCA mutations are found in approximately 5% of breast cancer patients.
Reference:
https://www.pharmatimes.com/news/lynparza_shows_promise_in_preventing_cancer_recurrence_1371212
Global shipping costs have climbed to $4,000–$4,500 in October from $2,000–$2,500 in February 2026. Freight rates, which had eased through much of 2025 and early 2026 as the demand-supply balance improved, have rebounded sharply in recent months. The increase has brought shipping costs back into focus for businesses dependent on international cargo movement.
The U.S. Food and Drug Administration (FDA) has finalized guidance outlining how manufacturers should report post-approval manufacturing changes for biosimilar and interchangeable biosimilar products. The guidance provides greater regulatory clarity on changes involving production processes, manufacturing sites, analytical methods, raw materials, and process controls. It aims to ensure product quality while reducing unnecessary regulatory burden.
A significant uptick in M&A activity in the biosimilars sector is being driven by FDA regulatory reforms, a maturing patent litigation framework and a looming patent cliff — $200 billion of branded products are facing patent expiration by 2030.
The Drewry World Container Index edged lower this week as falling Asia-Europe rates outweighed firmer pricing on the Transpacific, with carriers preparing another round of blank sailings ahead of China’s Golden Week holiday.
On 14 July 2026, the European Parliamentary Research Service (EPRS) published a comprehensive briefing on PFAS (per- and polyfluoroalkyl substances), also known as ‘forever chemicals’. The document is intended to serve as a technical basis for MEPs in their upcoming political decisions on PFAS regulation and summarises the current state of scientific knowledge, regulation and procedures.
Following a series of typhoon disruptions in East China during the month of August, major ports including Shanghai and Ningbo continue to experience congestion and operational recovery challenges. Industry reports indicate that vessel schedules, yard operations, and equipment circulation remain affected as terminals work through accumulated backlogs from successive storm events.
Under REACH Annex XVII Entry 78, the EU has banned the placing on the market of synthetic polymer microparticles (SPMs) unless a specific derogation applies. Derogations exist for essential uses such as:
As a result of the amendment of the CLP Regulation (Regulation (EC) No 1272/2008 on the classification, labelling and packaging of substances and mixtures), new hazard classes have entered into force.
In a converging policy shift on both sides of the Atlantic, European regulators this week published a roadmap toward fully replacing animal testing for chemical safety assessments, while the US Environmental Protection Agency issued a rare update to its list of alternative test methods.